Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

Table 4

Summary of characteristics of the present study and previous studies using carboplatin plus nab-paclitaxel in patients with advanced non-small-cell lung cancer and with interstitial lung disease in first-line settings.

Reference	No. of patients	Study patients	Study design	AE-ILD, n (%)	ORR (%)	Median PFS (months)	MST (months)
[19]	9	NSCLC with ILD	Retrospective	0 (0)	55.6	5.8	11.5
[20]	12	NSCLC with ILD	Retrospective	1 (8.3)	66.7	5.1	14.9
[21]	8	SCC with ILD	Retrospective	0 (0)	50.0	5.6	8.1
Present study	9	NSCLC with ILD	Retrospective	0 (0)	77.8	5.8	8.0

AE-ILD: acute exacerbation of interstitial lung disease; ORR: overall response rate; PFS: progression-free survival; MST: median survival time; NSCLC: non-small-cell lung cancer; SCC: squamous cell carcinoma.